CompletedPhase 2NCT05308472
Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
Studying Autosomal erythropoietic protoporphyria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Disc Medicine, Inc
- Principal Investigator
- Will Savage, MD PhDDisc Medicine
- Intervention
- DISC-1459(drug)
- Enrollment
- 75 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (9)
- University of Alabama Hospital, Birmingham, Alabama, United States
- University of California San Francisco, San Francisco, California, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mount Sinai Hospital, New York, New York, United States
- Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
- Einstein Medical Center, Philadelphia, Pennsylvania, United States
- University of Texas, Galveston, Texas, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05308472 on ClinicalTrials.govOther trials for Autosomal erythropoietic protoporphyria
Additional recruiting or active studies for the same condition.
See all trials for Autosomal erythropoietic protoporphyria →